Interestingly, one patient (P20) with 90% residual tumor had human leukocyte antigen (HLA)-A copy number loss along with low expression of HLA-I and HLA-II molecules (Supplementary Fig. 4), which we speculated as being related to the limited benefits via hindering antigen presentation and immune evasion21. The gene discussed is HLA-A; the disease is neoplasm.